Latent and activated brain flora: Human herpesviruses, endogenous retroviruses, coronaviruses, and Chlamydia and their role in neurological disease

Emerging Neurological Infections

Volumn , Issue , 2005, Pages 363-396

  Mayne, Michael ^a   Johnston, J B ^b  

^a UNIVERSITY OF MANITOBA   (Canada)

^b ROBARTS RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 78650210338     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (237)

1. Johnson RT. The virology of demyelinating diseases. Ann Neurol 1994; 36:S54-S60.
2. Osame M, Izumo S, Igata A, Matsumoto M, Matsumoto T, Sonoda S, Tara M, Shibata Y. Blood transfusion and HTLV-I associated myelopathy. Lancet 1986; 2:104-105.
3. Osame M, Usuku K, Izumo S, Ijichi N, Amitani H, Igata A, Matsumoto M, Tara M. HTLV-I associated myelopathy, a new clinical entity. Lancet 1986; 1:1031-1032.
4. Brew BJ. AIDS dementia complex. Neurol Clin 1999; 17:861-881.
5. Tardieu M. HIV-1-related central nervous system diseases. Curr Opin Neurol 1999; 12:377-381.
6. Ranger S, Patillaud S, Denis F, Himmich A, Sangare A, M’Boup S, Itoua-N’Gaporo A, Prince-David M, Chout R, Cevallos R. Seroepidemiology of human herpesvirus-6 in pregnant women from different parts of the world. J Med Virol 1991; 34:194-198.
7. Levy JA, Ferro F, Greenspan D, Lennette ET. Frequent isolation of HHV-6 from saliva and high seroprevalence of the virus in the population. Lancet 1990; 335:1047-1050.
8. Stoeckle MY. The spectrum of human herpesvirus 6 infection: from roseola infantum to adult disease. Annu Rev Med 2000; 51:423-430.
9. Dewhurst S, McIntyre K, Schnabel K, Hall CB. Human herpesvirus 6 (HHV-6) variant B accounts for the majority of symptomatic primary HHV-6 infections in a population of U.S. infants. J Clin Microbiol 1993; 31:416-418.
10. Caserta MT, Hall CB, Schnabel K, Long CE, D’Heron N. Primary human herpesvirus 7 infection: a comparison of human herpesvirus 7 and human herpesvirus 6 infections in children. J Pediatr 1998; 133:386-389.
11. Yamanishi K, Okuno T, Shiraki K, Takahashi M, Kondo T, Asano Y, Kurata T. Identification of human herpesvirus-6 as a causal agent for exanthem subitum. Lancet 1988; 1:1065-1067.
12. Dewhurst S, Chandran B, McIntyre K, Schnabel K, Hall CB. Phenotypic and genetic polymorphisms among human herpesvirus-6 isolates from North American infants. Virology 1992; 190:490-493.
13. Asano Y, Yoshikawa T, Suga S, Kobayashi I, Nakashima T, Yazaki T, Kajita Y, Ozaki T. Clinical features of infants with primary human herpesvirus 6 infection (exanthem subitum, roseola infantum). Pediatrics 1994; 93:104-108.
14. Kimberlin DW, Whitley RJ. Human herpesvirus-6: neurologic implications of a newly-described viral pathogen. J Neurovirol 1998; 4:474-485.
15. DesJardin JA, Gibbons L, Cho E, Supran SE, Falagas ME, Werner BG, Snydman DR. Human herpesvirus 6 reactivation is associated with cytomegalovirus infection and syndromes in kidney transplant recipients at risk for primary cytomegalovirus infection. J Infect Dis 1998; 178:1783-1786.
16. Cone RW, Huang ML, Corey L, Zeh J, Ashley R, Bowden R. Human herpesvirus 6 infections after bone marrow transplantation: clinical and virologic manifestations. J Infect Dis 1999; 179:311-318.
17. Lau YL, Peiris M, Chan GC, Chan AC, Chiu D, Ha SY. Primary human herpes virus 6 infection transmitted from donor to recipient through bone marrow infusion. Bone Marrow Transplant 1998; 21:1063-1066.
18. Buchbinder S, Elmaagacli AH, Schaefer UW, Roggendorf M. Human herpesvirus 6 is an important pathogen in infectious lung disease after allogeneic bone marrow transplantation. Bone Marrow Transplant 2000; 26:639-644.
19. Desachy A, Ranger-Rogez S, Francois B, Venot C, Traccard I, Gastinne H, Denis F, Vignon P. Reactivation of human herpesvirus type 6 in multiple organ failure syndrome. Clin Infect Dis 2001; 32:197-203.
20. Yoshikawa T, Asano Y. Central nervous system complications in human herpesvirus-6 infection. Brain Dev 2000; 22:307-314.
21. Hall CB, Caserta MT, Schnabel KC, Long C, Epstein LG, Insel RA, Dewhurst S. Persistence of human herpesvirus 6 according to site and variant: possible greater neurotropism of variant A. Clin Infect Dis 1998; 26:132-137.
22. Imbert-Marcille BM, Tang XW, Lepelletier D, Besse B, Moreau P, Billaudel S, Milpied N. Human herpesvirus 6 infection after autologous or allogeneic stem cell transplantation: a single-center prospective longitudinal study of 92 patients. Clin Infect Dis 2000; 31:881-886.
23. Kadakia MP. Human herpesvirus 6 infection and associated pathogenesis following bone marrow transplantation. Leuk Lymphoma 1998; 31:251-266.
24. Rogers J, Rohal S, Carrigan DR, Kusne S, Knox KK, Gayowski T, Wagener MM, Fung JJ, Singh N. Human herpesvirus-6 in liver transplant recipients: role in pathogenesis of fungal infections, neurologic complications, and outcome. Transplantation 2000; 69:2566-2573.
25. Bosi A, Zazzi M, Amantini A, Cellerini M, Vannucchi AM, De Milito A, Guidi S, Saccardi R, Lombardini L, Laszlo D, Rossi Ferrini P. Fatal herpesvirus 6 encephalitis after unrelated bone marrow transplant. Bone Marrow Transplant 1998; 22:285-288.
26. Paterson DL, Singh N, Gayowski T, Carrigan DR, Marino IR. Encephalopathy associated with human herpesvirus 6 in a liver transplant recipient. Liver Transpl Surg 1999; 5:454-455.
27. Singh N, Paterson DL. Encephalitis caused by human herpesvirus-6 in transplant recipients: relevance of a novel neurotropic virus. Transplantation 2000; 69:2474-2479.
28. Schmidt CA, Wilbron F, Weiss K, Brinkmann V, Oettle H, Lohmann R, Langrehr JM, Neuhaus P, Siegert W. A prospective study of human herpesvirus type 6 detected by polymerase chain reaction after liver transplantation. Transplantation 1996; 61:662-664.
29. Clark DA. Human herpesvirus 6. Rev Med Virol 2000; 10:155-173.
30. Knox KK, Carrigan DR. Active HHV-6 infection in the lymph nodes of HIVinfected patients: in vitro evidence that HHV-6 can break HIV latency. J Acquir Immune Defic Syndr Hum Retrovirol 1996; 11:370-378.
31. Lusso P, Ensoli B, Markham PD, Ablashi DV, Salahuddin SZ, Tschachler E, Wong-Staal F, Gallo RC. Productive dual infection of human CD4+ T lymphocytes by HIV-1 and HHV- 6. Nature 1989; 337:370-373.
32. Lusso P, De Maria A, Malnati M, Lori F, DeRocco SE, Baseler M, Gallo RC. Induction of CD4 and susceptibility to HIV-1 infection in human CD8+ T lymphocytes by human herpesvirus 6. Nature 1991; 349:533-535.
33. Grivel JC, Ito Y, Faga G, Santoro F, Shaheen F, Malnati MS, Fitzgerald W, Lusso P, Margolis L. Suppression of CCR5-but not CXCR4-tropic HIV-1 in lymphoid tissue by human herpesvirus 6. Nat Med 2001; 7:1232-1235.
34. Dolcetti R, Di Luca D, Carbone A, Mirandola P, De Vita S, Vaccher E, Sighinolfi L, Gloghini A, Tirelli U, Cassai E, Boiocchi M. Human herpesvirus 6 in human immunodeficiency virus-infected individuals: association with early histologic phases of lymphadenopathy syndrome but not with malignant lymphoproliferative disorders. J Med Virol 1996; 48:344-353.
35. Fabio G, Knight SN, Kidd IM, Noibi SM, Johnson MA, Emery VC, Griffiths PD, Clark DA. Prospective study of human herpesvirus 6, human herpesvirus 7, and cytomegalovirus infections in human immunodeficiency virus-positive patients. J Clin Microbiol 1997; 35:2657-2659.
36. Geraminejad P, Memar O, Aronson I, Rady PL, Hengge U, Tyring SK. Kaposi’s sarcoma and other manifestations of human herpesvirus 8. J Am Acad Dermatol 2002; 47:641-655.
37. Grulich AE, Dore GJ, Brew BJ. Human herpesvirus 8 and protection from AIDS dementia complex. Herpes 2000; 7:38-40.
38. Chan PK, Ng HK, Cheung JL, Cheng AF. Survey for the presence and distribution of human herpesvirus 8 in healthy brain. J Clin Microbiol 2000; 38:2772-2773.
39. Polk S, Munoz A, Sacktor NC, Jenkins FJ, Cohen B, Miller EN, Jacobson LP. A case-control study of HIV-1-related dementia and co-infection with HHV-8. Neurology 2002; 59:950-953.
40. Anlar B, Pinar A, Yasar Anlar F, Engin D, Ustacelebi S, Kocagoz T, Us D, Akduman D, Yalaz K. Viral studies in the cerebrospinal fluid in subacute sclerosing panencephalitis. J Infect 2002; 44:176-180.
41. Ebers GC, Kukay K, Bulman DE, Sadovnick AD, Rice G, Anderson C, Armstrong H, Cousin K, Bell RB, Hader W, Paty DW, Hashimoto S, Oger J, Duquette P, Warren S, Gray T, P OC, Nath A, Auty A, Metz L, et al. A full genome search in multiple sclerosis. Nat Genet 1996; 13:472-476.
42. Ebers GC, Sadovnick AD. The role of genetic factors in multiple sclerosis susceptibility. J Neuroimmunol 1994; 54:1-17.
43. Paty DW, Noseworthy JH, Ebers GC. Diagnosis of multiple sclerosis. In: Paty DW, Ebers GC, eds. Multiple Sclerosis. Philadelphia: FA Davis Company, 1998:93-97.
44. Challoner PB, Smith KT, Parker JD, MacLeod DL, Coulter SN, Rose TM, Schultz ER, Bennett JL, Garber RL, Chang M, et al. Plaque-associated expression of human herpesvirus 6 in multiple sclerosis. Proc Natl Acad Sci U S A 1995; 92:7440-7444.
45. Caserta MT, Hall CB, Schnabel K, McIntyre K, Long C, Costanzo M, Dewhurst S, Insel R, Epstein LG. Neuroinvasion and persistence of human herpesvirus 6 in children. J Infect Dis 1994; 170:1586-1589.
46. Blumberg BM, Mock DJ, Powers JM, Ito M, Assouline JG, Baker JV, Chen B, Goodman AD. The HHV6 paradox: ubiquitous commensal or insidious pathogen? A two-step in situ PCR approach. J Clin Virol 2000; 16:159-178.
47. Goodman AD, Mock DJ, Powers JM, Baker JV, Blumberg BM. Human herpesvirus 6 genome and antigen in acute multiple sclerosis lesions. J Infect Dis 2003; 187(9):1365-1376.
48. Cermelli C, Berti R, Soldan SS, Mayne M, D’ambrosia JM, Ludwin SK, Jacobson S. High frequency of human herpesvirus 6 DNA in multiple sclerosis plaques isolated by laser microdissection. J Infect Dis 2003; 187(9):1377-1387.
49. Knox KK, Brewer JH, Henry JM, Harrington DJ, Carrigan DR. Human herpesvirus 6 and multiple sclerosis: systemic active infections in patients with early disease. Clin Infect Dis 2000; 31:894-903.
50. Alvarez-Lafuente R, Martin-Estefania C, de Las Heras V, Castrillo C, Picazo JJ, Varela de Seijas E, Gonzalez RA. Active human herpesvirus 6 infection in patients with multiple sclerosis. Arch Neurol 2002; 59:929-933.
51. Mayne M, Krishnan J, Metz L, Nath A, Auty A, Sahai BM, Power C. Infrequent detection of human herpesvirus 6 DNA in peripheral blood mononuclear cells from multiple sclerosis patients. Ann Neurol 1998; 44:391-394.
52. Rotola A, Cassai E, Tola MR, Granieri E, Di Luca D. Human herpesvirus 6 is latent in peripheral blood of patients with relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry 1999; 67:529-531.
53. Akhyani N, Berti R, Brennan MB, Soldan SS, Eaton JM, McFarland HF, Jacobson S. Tissue distribution and variant characterization of human herpesvirus (HHV)-6:increased prevalence of HHV-6A in patients with multiple sclerosis. J Infect Dis 2000; 182:1321-1325.
54. Ablashi DV, Eastman HB, Owen CB, Roman MM, Friedman J, Zabriskie JB, Peterson DL, Pearson GR, Whitman JE. Frequent HHV-6 reactivation in multiple sclerosis (MS) and chronic fatigue syndrome (CFS) patients. J Clin Virol 2000; 16:179-191.
55. Kim JS, Lee KS, Park JH, Kim MY, Shin WS. Detection of human herpesvirus 6 variant A in peripheral blood mononuclear cells from multiple sclerosis patients. Eur Neurol 2000; 43:170-173.
56. Soldan SS, Leist TP, Juhng KN, McFarland HF, Jacobson S. Increased lymphoproliferative response to human herpesvirus type 6A variant in multiple sclerosis patients. Ann Neurol 2000; 47:306-313.
57. Wandinger K, Jabs W, Siekhaus A, Bubel S, Trillenberg P, Wagner H, Wessel K, Kirchner H, Hennig H. Association between clinical disease activity and Epstein-Barr virus reactivation in MS. Neurology 2000; 55:178-184.
58. Wagner HJ, Hennig H, Jabs WJ, Siekhaus A, Wessel K, Wandinger KP. Altered prevalence and reactivity of anti-Epstein-Barr virus antibodies in patients with multiple sclerosis. Viral Immunol 2000; 13:497-502.
59. Ascherio A, Munch M. Epstein-Barr virus and multiple sclerosis. Epidemiology 2000; 11:220-224.
60. Sanders VJ, Waddell AE, Felisan SL, Li X, Conrad AJ, Tourtellotte WW. Herpes simplex virus in postmortem multiple sclerosis brain tissue. Arch Neurol 1996; 53:125-133.
61. Sanders VJ, Felisan S, Waddell A, Tourtellotte WW. Detection of herpesviridae in postmortem multiple sclerosis brain tissue and controls by polymerase chain reaction. J Neurovirol 1996; 2:249-258.
62. Ferrante P, Mancuso R, Pagani E, Guerini FR, Calvo MG, Saresella M, Speciale L, Caputo D. Molecular evidences for a role of HSV-1 in multiple sclerosis clinical acute attack. J Neurovirol 2000; 6(suppl 2):S109-S114.
63. Cortese I, Capone S, Luchetti S, Cortese R, Nicosia A. Cross-reactive phage-displayed mimotopes lead to the discovery of mimicry between HSV-1 and a brainspecific protein. J Neuroimmunol 2001; 113:119-128.
64. Beatty WL, Morrison RP, Byrne GI. Persistent chlamydiae: from cell culture to a paradigm for chlamydial pathogenesis. Microbiol Rev 1994; 58:686-699.
65. Peeling RW, Brunham RC. Chlamydiae as pathogens: new species and new issues. Emerg Infect Dis 1996; 2:307-319.
66. Ward ME. The immunobiology and immunopathology of chlamydial infections. Apmis 1995; 103:769-796.
67. Beatty WL, Byrne GI, Morrison RP. Repeated and persistent infection with Chlamydia and the development of chronic inflammation and disease. Trends Microbiol 1994; 2:94-98.
68. Korman TM, Turnidge JD, Grayson ML. Neurological complications of chlamydial infections: case report and review. Clin Infect Dis 1997; 25:847-851.
69. Koskiniemi M, Gencay M, Salonen O, Puolakkainen M, Farkkila M, Saikku P, Vaheri A. Chlamydia pneumoniae associated with central nervous system infections. Eur Neurol 1996; 36:160-163.
70. Yucesan C, Sriram S. Chlamydia pneumoniae infection of the central nervous system. Curr Opin Neurol 2001; 14:355-359.
71. Heick A, Skriver E. Chlamydia pneumoniae-associated ADEM. Eur J Neurol 2000; 7:435-438.
72. Sriram S, Mitchell W, Stratton C. Multiple sclerosis associated with Chlamydia pneumoniae infection of the CNS. Neurology 1998; 50:571-572.
73. Sriram S, Stratton CW, Yao S, Tharp A, Ding L, Bannan JD, Mitchell WM. Chlamydia pneumoniae infection of the central nervous system in multiple sclerosis. Ann Neurol 1999; 46:6-14.
74. Sriram S, Yao SY, Stratton C, Calabresi P, Mitchell W, Ikejima H, Yamamoto Y. Comparative study of the presence of Chlamydia pneumoniae in cerebrospinal fluid of patients with clinically definite and monosymptomatic multiple sclerosis. Clin Diagn Lab Immunol 2002; 9:1332-1337.
75. Balin BJ, Gerard HC, Arking EJ, Appelt DM, Branigan PJ, Abrams JT, Whittum-Hudson JA, Hudson AP. Identification and localization of Chlamydia pneumoniae in the Alzheimer’s brain. Med Microbiol Immunol (Berl) 1998; 187:23-42.
76. Braun J, Laitko S, Treharne J, Eggens U, Wu P, Distler A, Sieper J. Chlamydia pneumoniae-a new causative agent of reactive arthritis and undifferentiated oligoarthritis. Ann Rheum Dis 1994; 53:100-105.
77. Elkind MS, Lin IF, Grayston JT, Sacco RL. Chlamydia pneumoniae and the risk of first ischemic stroke: The Northern Manhattan Stroke Study. Stroke 2000; 31:1521-1525.
78. Gran JT, Hjetland R, Andreassen AH. Pneumonia, myocarditis and reactive arthritis due to Chlamydia pneumoniae. Scand J Rheumatol 1993; 22:43-44.
79. Heuschmann PU, Neureiter D, Gesslein M, Craiovan B, Maass M, Faller G, Beck G, Neundoerfer B, Kolominsky-Rabas PL. Association between infection with Helicobacter pylori and Chlamydia pneumoniae and risk of ischemic stroke subtypes:results from a population-based case-control study. Stroke 2001; 32:2253-2258.
80. Madre JG, Garcia JL, Gonzalez RC, Montero JM, Paniagua EB, Escribano JR, Martinez JD, Cenjor RF. Association between seropositivity to Chlamydia pneumoniae and acute ischaemic stroke. Eur J Neurol 2002; 9:303-306.
81. Moling O, Pegoretti S, Rielli M, Rimenti G, Vedovelli C, Pristera R, Mian P. Chlamydia pneumoniae-reactive arthritis and persistent infection. Br J Rheumatol 1996; 35:1189-1190.
82. Saario R, Toivanen A. Chlamydia pneumoniae as a cause of reactive arthritis. Br J Rheumatol 1993; 32:1112.
83. Gieffers J, Pohl D, Treib J, Dittmann R, Stephan C, Klotz K, Hanefeld F, Solbach W, Haass A, Maass M. Presence of Chlamydia pneumoniae DNA in the cerebral spinal fluid is a common phenomenon in a variety of neurological diseases and not restricted to multiple sclerosis. Ann Neurol 2001; 49:585-589.
84. Hammerschlag MR, Ke Z, Lu F, Roblin P, Boman J, Kalman B. Is Chlamydia pneumoniae present in brain lesions of patients with multiple sclerosis? J Clin Microbiol 2000; 38:4274-4276.
85. Ke Z, Lu F, Roblin P, Boman J, Hammerschlag MR, Kalman B. Lack of detectable Chlamydia pneumoniae in brain lesions of patients with multiple sclerosis. Ann Neurol 2000; 48:400.
86. Layh-Schmitt G, Bendl C, Hildt U, Dong-Si T, Juttler E, Schnitzler P, Grond-Ginsbach C, Grau AJ. Evidence for infection with Chlamydia pneumoniae in a subgroup of patients with multiple sclerosis. Ann Neurol 2000; 47:652-655.
87. Sotgiu S, Piana A, Pugliatti M, Sotgiu A, Deiana GA, Sgaramella E, Muresu E, Rosati G. Chlamydia pneumoniae in the cerebrospinal fluid of patients with multiple sclerosis and neurological controls. Mult Scler 2001; 7:371-374.
88. Sriram S. Failure to detect Chlamydia pneumoniae in the central nervous system of patients with MS. Neurology 2000; 55:1423-1424.
89. Tsai JC, Gilden DH. Chlamydia pneumoniae and multiple sclerosis: no significant association. Trends Microbiol 2001; 9:152-154.
90. Kaufman M, Gaydos CA, Sriram S, Boman J, Tondella ML, Norton HJ. Is Chlamydia pneumoniae found in spinal fluid samples from multiple sclerosis patients? Conflicting results. Mult Scler 2002; 8:289-294.
91. Correale J, de los Milagros Bassani Molinas M. Oligoclonal bands and antibody responses in multiple sclerosis. J Neurol 2002; 249:375-389.
92. Yao SY, Stratton CW, Mitchell WM, Sriram S. CSF oligoclonal bands in MS include antibodies against Chlamydophila antigens. Neurology 2001; 56:1168-1176.
93. Derfuss T, Gurkov R, Then Bergh F, Goebels N, Hartmann M, Barz C, Wilske B, Autenrieth I, Wick M, Hohlfeld R, Meinl E. Intrathecal antibody production against Chlamydia pneumoniae in multiple sclerosis is part of a polyspecific immune response. Brain 2001; 124:1325-1235.
94. Krametter D, Niederwieser G, Berghold A, Birnbaum G, Strasser-Fuchs S, Hartung HP, Archelos JJ. Chlamydia pneumoniae in multiple sclerosis: humoral immune responses in serum and cerebrospinal fluid and correlation with disease activity marker. Mult Scler 2001; 7:13-18.
95. Krametter D, Niederwieser G, Berghold A, Birnbaum G, Strasser-Fuchs S, Hartung HP, Archelos JJ. Chlamydia pneumoniae-specific humoral immune responses and clinical disease parameters in multiple sclerosis. Ann Neurol 2001; 49:135.
96. Hao Q, Miyashita N, Matsui M, Wang HY, Matsushima T, Saida T. Chlamydia pneumoniae infection associated with enhanced MRI spinal lesions in multiple sclerosis. Mult Scler 2002; 8:436-440.
97. Du C, Yao SY, Ljunggren-Rose A, Sriram S. Chlamydia pneumoniae infection of the central nervous system worsens experimental allergic encephalitis. J Exp Med 2002; 196:1639-1644.
98. Lenz DC, Lu L, Conant SB, Wolf NA, Gerard HC, Whittum-Hudson JA, Hudson AP, Swanborg RH. A Chlamydia pneumoniae-specific peptide induces experimental autoimmune encephalomyelitis in rats. J Immunol 2001; 167:1803-1808.
99. Bruunsgaard H, Ostergaard L, Andersen-Ranberg K, Jeune B, Pedersen BK. Proinflammatory cytokines, antibodies to Chlamydia pneumoniae and age-associated diseases in Danish centenarians: is there a link? Scand J Infect Dis 2002; 34:493-499.
100. MacIntyre A, Hammond CJ, Little CS, Appelt DM, Balin BJ. Chlamydia pneumoniae infection alters the junctional complex proteins of human brain microvascular endothelial cells. FEMS Microbiol Lett 2002; 217:167-172.
101. Balin BJ, Appelt DM. Role of infection in Alzheimer’s disease. J Am Osteopath Assoc 2001; 101:S1-S6.
102. Renvoize EB, Awad IO, Hambling MH. A sero-epidemiological study of conventional infectious agents in Alzheimer’s disease. Age Ageing 1987; 16:311-314.
103. Gieffers J, Reusche E, Solbach W, Maass M. Failure to detect Chlamydia pneumoniae in brain sections of Alzheimer’s disease patients. J Clin Microbiol 2000; 38:881-882.
104. Ring RH, Lyons JM. Failure to detect Chlamydia pneumoniae in the late-onset Alzheimer’s brain. J Clin Microbiol 2000; 38:2591-2594.
105. Mahley RW, Rall SC Jr. Apolipoprotein E: far more than a lipid transport protein. Annu Rev Genomics Hum Genet 2000; 1:507-537.
106. Gerard HC, Wang GF, Balin BJ, Schumacher HR, Hudson AP. Frequency of apolipoprotein E (APOE) allele types in patients with Chlamydia-associated arthritis and other arthritides. Microb Pathog 1999; 26:35-43.
107. Chapman J, Vinokurov S, Achiron A, Karussis DM, Mitosek-Szewczyk K, Birnbaum M, Michaelson DM, Korczyn AD. APOE genotype is a major predictor of long-term progression of disability in MS. Neurology 2001; 56:312-316.
108. Fazekas F, Strasser-Fuchs S, Kollegger H, Berger T, Kristoferitsch W, Schmidt H, Enzinger C, Schiefermeier M, Schwarz C, Kornek B, Reindl M, Huber K, Grass R, Wimmer G, Vass K, Pfeiffer KH, Hartung HP, Schmidt R. Apolipoprotein E epsilon 4 is associated with rapid progression of multiple sclerosis. Neurology 2001; 57:853-857.
109. Compton SR, Barthold SW, Smith AL. The cellular and molecular pathogenesis of coronaviruses. Lab Anim Sci 1993; 43:15-28.
110. Lai MM. Coronavirus: organization, replication and expression of genome. Annu Rev Microbiol 1990; 44:303-333.
111. Lai MM, Cavanagh D. The molecular biology of coronaviruses. Adv Virus Res 1997; 48:1-100.
112. Myint SH. Human coronaviruses-a brief review. Rev Med Virol 1994; 4:35-46.
113. Arbour N, Day R, Newcombe J, Talbot PJ. Neuroinvasion by human respiratory coronaviruses. J Virol 2000; 74:8913-8921.
114. Collins AR. Human macrophages are susceptible to coronavirus OC43. Adv Exp Med Biol 1998; 440:635-639.
115. Patterson S, Macnaughton MR. Replication of human respiratory coronavirus strain 229E in human macrophages. J Gen Virol 1982; 60:307-314.
116. Arbour N, Cote G, Lachance C, Tardieu M, Cashman NR, Talbot PJ. Acute and persistent infection of human neural cell lines by human coronavirus OC43. J Virol 1999; 73:3338-3350.
117. Arbour N, Ekande S, Cote G, Lachance C, Chagnon F, Tardieu M, Cashman NR, Talbot PJ. Persistent infection of human oligodendrocytic and neuroglial cell lines by human coronavirus 229E. J Virol 1999; 73:3326-3337.
118. Lachance C, Arbour N, Cashman NR, Talbot PJ. Involvement of aminopeptidase N (CD13) in infection of human neural cells by human coronavirus 229E. J Virol 1998; 72:6511-6519.
119. Lane TE, Buchmeier MJ. Murine coronavirus infection: a paradigm for virusinduced demyelinating disease. Trends Microbiol 1997; 5:9-14.
120. Houtman JJ, Fleming JO. Pathogenesis of mouse hepatitis virus-induced demyelination. J Neurovirol 1996; 2:361-376.
121. Matthews AE, Weiss SR, Paterson Y. Murine hepatitis virus-a model for virusinduced CNS demyelination. J Neurovirol 2002; 8:76-85.
122. Stohlman SA, Hinton DR. Viral induced demyelination. Brain Pathol 2001; 11:92-106.
123. Murray RS, Cai GY, Hoel K, Zhang JY, Soike KF, Cabirac GF. Coronavirus infects and causes demyelination in primate central nervous system. Virology 1992; 188:274-284.
124. Murray RS, Cai GY, Soike KF, Cabirac GF. Further observations on coronavirus infection of primate CNS. J Neurovirol 1997; 3:71-75.
125. Haspel MV, Lampert PW, Oldstone MB. Temperature-sensitive mutants of mouse hepatitis virus produce a high incidence of demyelination. Proc Natl Acad Sci U S A 1978; 75:4033-4036.
126. Weiner LP. Pathogenesis of demyelination induced by a mouse hepatitis. Arch Neurol 1973; 28:298-303.
127. Das Sarma J, Fu L, Tsai JC, Weiss SR, Lavi E. Demyelination determinants map to the spike glycoprotein gene of coronavirus mouse hepatitis virus. J Virol 2000; 74:9206-9213.
128. Dandekar AA, Wu GF, Pewe L, Perlman S. Axonal damage is T cell mediated and occurs concomitantly with demyelination in mice infected with a neurotropic coronavirus. J Virol 2001; 75:6115-6120.
129. Fleming JO, Wang FI, Trousdale MD, Hinton DR, Stohlman SA. Interaction of immune and central nervous systems: contribution of anti-viral Thy-1+ cells to demyelination induced by coronavirus JHM. Reg Immunol 1993; 5:37-43.
130. Lane TE, Liu MT, Chen BP, Asensio VC, Samawi RM, Paoletti AD, Campbell IL, Kunkel SL, Fox HS, Buchmeier MJ. A central role for CD4(+) T cells and RANTES in virus-induced central nervous system inflammation and demyelination. J Virol 2000; 74:1415-1424.
131. Wang FI, Stohlman SA, Fleming JO. Demyelination induced by murine hepatitis virus JHM strain (MHV-4) is immunologically mediated. J Neuroimmunol 1990; 30:31-41.
132. Dandekar AA, Perlman S. Virus-induced demyelination in nude mice is mediated by gamma delta T cells. Am J Pathol 2002; 161:1255-1263.
133. Matthews AE, Lavi E, Weiss SR, Paterson Y. Neither B cells nor T cells are required for CNS demyelination in mice persistently infected with MHV-A59. J Neurovirol 2002; 8:257-264.
134. Haring JS, Pewe LL, Perlman S. Bystander CD8 T cell-mediated demyelination after viral infection of the central nervous system. J Immunol 2002; 169:1550-1555.
135. Redwine JM, Buchmeier MJ, Evans CF. In vivo expression of major histocompatibility complex molecules on oligodendrocytes and neurons during viral infection. Am J Pathol 2001; 159:1219-1224.
136. Tanaka R, Iwasaki Y, Koprowski H. Intracisternal virus-like particles in brain of a multiple sclerosis patient. J Neurol Sci 1976; 28:121-126.
137. Burks JS, DeVald BL, Jankovsky LD, Gerdes JC. Two coronaviruses isolated from central nervous system tissue of two multiple sclerosis patients. Science 1980; 209:933-934.
138. Cristallo A, Gambaro F, Biamonti G, Ferrante P, Battaglia M, Cereda PM. Human coronavirus polyadenylated RNA sequences in cerebrospinal fluid from multiple sclerosis patients. New Microbiol 1997; 20:105-114.
139. Murray RS, Brown B, Brian D, Cabirac GF. Detection of coronavirus RNA and antigen in multiple sclerosis brain. Ann Neurol 1992; 31:525-533.
140. Stewart JN, Mounir S, Talbot PJ. Human coronavirus gene expression in the brains of multiple sclerosis patients. Virology 1992; 191:502-505.
141. Salmi A, Ziola B, Hovi T, Reunanen M. Antibodies to coronaviruses OC43 and 229E in multiple sclerosis patients. Neurology 1982; 32:292-295.
142. Salmi A, Ziola B, Reunanen M, Julkunen I, Wager O. Immune complexes in serum and cerebrospinal fluid of multiple sclerosis patients and patients with other neurological diseases. Acta Neurol Scand 1982; 66:1-15.
143. Dessau RB, Lisby G, Frederiksen JL. Coronaviruses in brain tissue from patients with multiple sclerosis. Acta Neuropathol (Berl) 2001; 101:601-604.
144. Dessau RB, Lisby G, Frederiksen JL. Coronaviruses in spinal fluid of patients with acute monosymptomatic optic neuritis. Acta Neurol Scand 1999; 100:88-91.
145. Sorensen O, Collins A, Flintoff W, Ebers G, Dales S. Probing for the human coronavirus OC43 in multiple sclerosis. Neurology 1986; 36:1604-1606.
146. Fleming JO, el Zaatari FA, Gilmore W, Berne JD, Burks JS, Stohlman SA, Tourtellotte WW, Weiner LP. Antigenic assessment of coronaviruses isolated from patients with multiple sclerosis. Arch Neurol 1988; 45:629-633.
147. Madden DL, Wallen WC, Houff SA, Leinikki PA, Sever JL, Holmes KA, Castellano GA, Shekarchi IC. Coronavirus antibodies in sera from patients with multiple sclerosis and matched controls. Arch Neurol 1981; 38:209-210.
148. Boucher A, Denis F, Duquette P, Talbot PJ. Generation from multiple sclerosis patients of long-term T-cell clones that are activated by both human coronavirus and myelin antigens. Adv Exp Med Biol 2001; 494:355-362.
149. Talbot PJ, Paquette JS, Ciurli C, Antel JP, Ouellet F. Myelin basic protein and human coronavirus 229E cross-reactive T cells in multiple sclerosis. Ann Neurol 1996; 39:233-240.
150. Edwards JA, Denis F, Talbot PJ. Activation of glial cells by human coronavirus OC43 infection. J Neuroimmunol 2000; 108:73-81.
151. Collins AR. In vitro detection of apoptosis in monocytes/macrophages infected with human coronavirus. Clin Diagn Lab Immunol 2002; 9:1392-1395.
152. Lower R, Lower J, Kurth R. The viruses in all of us: characteristics and biological significance of human endogenous retrovirus sequences. Proc Natl Acad Sci U S A 1996; 93:5177-5184.
153. Wilkinson DA, Mager DL, Leong JC. Endogenous human retroviruses. In: Levy JA, ed. The Retroviridae. New York, NY: Plenum Press, 1994:465-535.
154. Larsson E, Andersson G. Beneficial role of human endogenous retroviruses: facts and hypotheses. Scand J Immunol 1998; 48:329-338.
155. Krieg AM, Gourley MF, Perl A. Endogenous retroviruses: potential etiologic agents in autoimmunity. FASEB J 1992; 6:2537-2544.
156. Lower R. The pathogenic potential of endogenous retroviruses: facts and fantasies. Trends Microbiol 1999; 7:350-356.
157. Nakagawa K, Harrison LC. The potential roles of endogenous retroviruses in autoimmunity. Immunol Rev 1996; 152:193-236.
158. Rasmussen HB, Clausen J. Possible involvement of endogenous retroviruses in the development of autoimmune disorders, especially multiple sclerosis. Acta Neurol Scand Suppl 1997; 169:32-37.
159. Christensen T, Dissing Sorensen P, Riemann H, Hansen HJ, Moller-Larsen A. Expression of sequence variants of endogenous retrovirus RGH in particle form in multiple sclerosis. Lancet 1998; 352:1033.
160. Christensen T, Dissing Sorensen P, Riemann H, Hansen HJ, Munch M, Haahr S, Moller-Larsen A. Molecular characterization of HERV-H variants associated with multiple sclerosis. Acta Neurol Scand 2000; 101:229-238.
161. Perron H, Lalande B, Gratacap B, Laurent A, Genoulaz O, Geny C, Mallaret M, Schuller E, Stoebner P, Seigneurin JM. Isolation of retrovirus from patients with multiple sclerosis. Lancet 1991; 337:862-863.
162. Perron H, Garson JA, Bedin F, Beseme F, Paranhos-Baccala G, Komurian-Pradel F, Mallet F, Tuke PW, Voisset C, Blond JL, Lalande B, Seigneurin JM, Mandrand B. Molecular identification of a novel retrovirus repeatedly isolated from patients with multiple sclerosis. The Collaborative Research Group on Multiple Sclerosis. Proc Natl Acad Sci U S A 1997; 94:7583-7588.
163. Rasmussen HB, Geny C, Deforges L, Perron H, Tourtelotte W, Heltberg A, Clausen J. Expression of endogenous retroviruses in blood mononuclear cells and brain tissue from multiple sclerosis patients. Mult Scler 1995; 1:82-87.
164. Nakagawa K, Brusic V, McColl G, Harrison LC. Direct evidence for the expression of multiple endogenous retroviruses in the synovial compartment in rheumatoid arthritis. Arthritis Rheum 1997; 40:627-638.
165. Nelson PN, Lever AM, Smith S, Pitman R, Murray P, Perera SA, Westwood OM, Hay FC, Ejtehadi HD, Booth JC. Molecular investigations implicate human endogenous retroviruses as mediators of anti-retroviral antibodies in autoimmune rheumatic disease. Immunol Invest 1999; 28:277-289.
166. Conrad B, Weissmahr RN, Boni J, Arcari R, Schupbach J, Mach B. A human endogenous retroviral superantigen as candidate autoimmune gene in type I diabetes. Cell 1997; 90:303-313.
167. Konttinen YT, Kasna-Ronkainen L. Sjogren’s syndrome: viewpoint on pathogenesis. One of the reasons I was never asked to write a textbook chapter on it. Scand J Rheumatol Suppl 2002:15-22.
168. Deb-Rinker P, Klempan TA, O’Reilly RL, Torrey EF, Singh SM. Molecular characterization of a MSRV-like sequence identified by RDA from monozygotic twin pairs discordant for schizophrenia. Genomics 1999; 61:133-144.
169. Deb-Rinker P, O’Reilly RL, Torrey EF, Singh SM. Molecular characterization of a 2.7-kb, 12q13-specific, retroviral-related sequence isolated by RDA from monozygotic twin pairs discordant for schizophrenia. Genome 2002; 45:381-390.
170. Karlsson H, Bachmann S, Schroder J, McArthur J, Torrey EF, Yolken RH. Retroviral RNA identified in the cerebrospinal fluids and brains of individuals with schizophrenia. Proc Natl Acad Sci U S A 2001; 98:4634-4639.
171. Pani MA, Seidl C, Bieda K, Seissler J, Krause M, Seifried E, Usadel KH, Badenhoop K. Preliminary evidence that an endogenous retroviral long-terminal repeat (LTR13) at the HLA-DQB1 gene locus confers susceptibility to Addison’s disease. Clin Endocrinol (Oxf) 2002; 56:773-777.
172. Wang-Johanning F, Frost AR, Johanning GL, Khazaeli MB, LoBuglio AF, Shaw DR, Strong TV. Expression of human endogenous retrovirus k envelope transcripts in human breast cancer. Clin Cancer Res 2001; 7:1553-1560.
173. Schiavetti F, Thonnard J, Colau D, Boon T, Coulie PG. A human endogenous retroviral sequence encoding an antigen recognized on melanoma by cytolytic T lymphocytes. Cancer Res 2002; 62:5510-5516.
174. Depil S, Roche C, Dussart P, Prin L. Expression of a human endogenous retrovirus, HERV-K, in the blood cells of leukemia patients. Leukemia 2002; 16:254-259.
175. Patzke S, Lindeskog M, Munthe E, Aasheim HC. Characterization of a novel human endogenous retrovirus, HERV-H/F, expressed in human leukemia cell lines. Virology 2002; 303:164-173.
176. Sauter M, Schommer S, Kremmer E, Remberger K, Dolken G, Lemm I, Buck M, Best B, Neumann-Haefelin D, Mueller-Lantzsch N. Human endogenous retrovirus K10: expression of Gag protein and detection of antibodies in patients with seminomas. J Virol 1995; 69:414-421.
177. Perron H, Geny C, Laurent A, Mouriquand C, Pellat J, Perret J, Seigneurin JM. Leptomeningeal cell line from multiple sclerosis with reverse transcriptase activity and viral particles. Res Virol 1989; 140:551-561.
178. Perron H, Geny C, Genoulaz O, Pellat J, Perret J, Seigneurin JM. Antibody to reverse transcriptase of human retroviruses in multiple sclerosis. Acta Neurol Scand 1991; 84:507-513.
179. Perron H, Firouzi R, Tuke P, Garson JA, Michel M, Beseme F, Bedin F, Mallet F, Marcel E, Seigneurin JM, Mandrand B. Cell cultures and associated retroviruses in multiple sclerosis. Collaborative Research Group on MS. Acta Neurol Scand Suppl 1997; 169:22-31.
180. Lefebvre S, Hubert B, Tekaia F, Brahic M, Bureau JF. Isolation from human brain of six previously unreported cDNAs related to the reverse transcriptase of human endogenous retroviruses. AIDS Res Hum Retroviruses 1995; 11:231-237.
181. Blond JL, Beseme F, Duret L, O. Bouton O, F. Bedin F, H. Perron H, B. Mandrand B, Mallet F. Molecular characterization and placental expression of HERV-W, a new human endogenous retrovirus family. J Virol 1999; 73:1175-1185.
182. La Mantia G, Maglione D, Pengue G, Di Cristofano A, Simeone A, Lanfrancone L, Lania L. Identification and characterization of novel human endogenous retroviral sequences preferentially expressed in undifferentiated embryonal carcinoma cells. Nucleic Acids Res 1991; 19:1513-1520.
183. Jolivet-Reynaud C, Perron H, Ferrante P, Becquart L, Dalbon P, Mandrand B. Specificities of multiple sclerosis cerebrospinal fluid and serum antibodies against mimotopes. Clin Immunol 1999; 93:283-293.
184. Voisset C, Blancher A, Perron H, Mandrand B, Mallet F, Paranhos-Baccala G. Phylogeny of a novel family of human endogenous retrovirus sequences, HERV-W, in humans and other primates. AIDS Res Hum Retroviruses 1999; 15:1529-1533.
185. Perron H, Perin JP, Rieger F, Alliel PM. Particle-associated retroviral RNA and tandem RGH/HERV-W copies on human chromosome 7q: possible components of a ‘chain-reaction’ triggered by infectious agents in multiple sclerosis? J Neurovirol 2000; 6(suppl 2):S67-S75.
186. Mi S, Lee X, Li X, Veldman GM, Finnerty H, Racie L, LaVallie E, Tang XY, Edouard P, Howes S, Keith JC, McCoy JM. Syncytin is a captive retroviral envelope protein involved in human placental morphogenesis. Nature 2000; 403:785-789.
187. Blond JL, Lavillette D, Cheynet V, Bouton O, Oriol G, Chapel-Fernandes S, Mandrand B, Mallet F, Cosset FL. An envelope glycoprotein of the human endogenous retrovirus HERV-W is expressed in the human placenta and fuses cells expressing the type D mammalian retrovirus receptor. J Virol 2000; 74:3321-3329.
188. Lavillette D, Marin M, Ruggieri A, Mallet F, Cosset FL, Kabat D. The envelope glycoprotein of human endogenous retrovirus type W uses a divergent family of amino acid transporters/cell surface receptors. J Virol 2002; 76:6442-6452.
189. An DS, Xie Y, Chen IS. Envelope gene of the human endogenous retrovirus HERVW encodes a functional retrovirus envelope. J Virol 2001; 75:3488-3489.
190. Christensen T, Pedersen L, Sorensen PD, Moller-Larsen A. A transmissible human endogenous retrovirus. AIDS Res Hum Retroviruses 2002; 18:861-866.
191. Kwun HJ, Han HJ, Lee WJ, Kim HS, Jang KL. Transactivation of the human endogenous retrovirus K long terminal repeat by herpes simplex virus type 1 immediate early protein 0. Virus Res 2002; 86:93-100.
192. Haahr S, Sommerlund M, Christensen T, Jensen AW, Hansen HJ, Moller-Larsen A. A putative new retrovirus associated with multiple sclerosis and the possible involvement of Epstein-Barr virus in this disease. Ann N Y Acad Sci 1994; 724:148-156.
193. Haahr S, Munch M. The association between multiple sclerosis and infection with Epstein-Barr virus and retrovirus. J Neurovirol 2000; 6(suppl 2):S76-S79.
194. Sutkowski N, Conrad B, Thorley-Lawson DA, Huber BT. Epstein-Barr virus transactivates the human endogenous retrovirus HERV-K18 that encodes a superantigen. Immunity 2001; 15:579-589.
195. Perron H, Jouvin-Marche E, Michel M, Ounanian-Paraz A, Camelo S, Dumon A, Jolivet-Reynaud C, Marcel F, Souillet Y, Borel E, Gebuhrer L, Santoro L, Marcel S, Seigneurin JM, Marche PN, Lafon M. Multiple sclerosis retrovirus particles and recombinant envelope trigger an abnormal immune response in vitro, by inducing polyclonal Vbeta16 T-lymphocyte activation. Virology 2001; 287:321-332.
196. Clerici M, Fusi ML, Caputo D, Guerini FR, Trabattoni D, Salvaggio A, Cazzullo CL, Arienti D, Villa ML, Urnovitz HB, Ferrante P. Immune responses to antigens of human endogenous retroviruses in patients with acute or stable multiple sclerosis. J Neuroimmunol 1999; 99:173-182.
197. Trabattoni D, Ferrante P, Fusi ML, Saresella M, Caputo D, Urnovitz H, Cazzullo CL, Clerici M. Augmented type 1 cytokines and human endogenous retroviruses specific immune responses in patients with acute multiple sclerosis. J Neurovirol 2000; 6(suppl 2):S38-S41.
198. Menard A, Paranhos-Baccala G, Pelletier J, Mandrand B, Seigneurin JM, Perron H, Reiger F. A cytotoxic factor for glial cells: a new avenue of research for multiple sclerosis? Cell Mol Biol (Noisy-le-grand) 1997; 43:889-901.
199. Crow TJ. A re-evaluation of the viral hypothesis: is psychosis the result of retroviral integration at a site close to the cerebral dominance gene? Br J Psychiatry 1984; 145:243-253.
200. O’Reilly RL, Singh SM. Retroviruses and schizophrenia revisited. Am J Med Genet 1996; 67:19-24.
201. Yolken RH, Karlsson H, Yee F, Johnston-Wilson NL, Torrey EF. Endogenous retroviruses and schizophrenia. Brain Res Brain Res Rev 2000; 31:193-199.
202. Gonzalez-Scarano F, Baltuch G. Microglia as mediators of inflammatory and degenerative diseases. Annu Rev Neurosci 1999; 22:219-240.
203. Katsumata K, Ikeda H, Sato M, Ishizu A, Kawarada Y, Kato H, Wakisaka A, Koike T, Yoshiki T. Cytokine regulation of env gene expression of human endogenous retrovirus-R in human vascular endothelial cells. Clin Immunol 1999; 93:75-80.
204. Larsson E, Venables P, Andersson AC, et al. Tissue and differentiation specific expression on the endogenous retrovirus ERV3 (HERV-R) in normal human tissues and during induced monocytic differentiation in the U-937 cell line. Leukemia 1997; 11(suppl 3):142-144.
205. Larsson E, Venables PJ, Andersson AC, et al. Expression of the endogenous retrovirus ERV3 (HERV-R) during induced monocytic differentiation in the U-937 cell line. Int J Cancer 1996; 67:451-456.
206. Sibata M, Ikeda H, Katumata K, Takeuchi K, Wakisaka A, Yoshoki T. Human endogenous retroviruses: expression in various organs in vivo and its regulation in vitro. Leukemia 1997; 11(suppl 3):145-146.
207. Johnston JB, Silva C, Holden J, Warren KG, Clark AW, Power C. Monocyte activation and differentiation augment human endogenous retrovirus expression: implications for inflammatory brain diseases. Ann Neurol 2001; 50:434-442.
208. Lassmann H. The pathology of multiple sclerosis and its evolution. Philos Trans R Soc Lond B Biol Sci 1999; 354:1635-1640.
209. Cermelli C, Jacobson S. Viruses and multiple sclerosis. Viral Immunol 2000; 13:255-267.
210. Ichikawa HT, Williams LP, Segal BM. Activation of APCs through CD40 or Tolllike receptor 9 overcomes tolerance and precipitates autoimmune disease. J Immunol 2002; 169:2781-2787.
211. Karp CL. Interleukin-12: amiss in MS. Ann Neurol 1999; 45:689-692.
212. Karp CL, van Boxel-Dezaire AH, Byrnes AA, Nagelkerken L. Interferon-beta in multiple sclerosis: altering the balance of interleukin-12 and interleukin-10? Curr Opin Neurol 2001; 14:361-368.
213. Lien E, Ingalls RR. Toll-like receptors. Crit Care Med 2002; 30:S1-S11.
214. Zuany-Amorim C, Hastewell J, Walker C. Toll-like receptors as potential therapeutic targets for multiple diseases. Nat Rev Drug Discov 2002; 1:797-807.
215. Modlin RL. Mammalian toll-like receptors. Ann Allergy Asthma Immunol 2002; 88:543-547.
216. Simmons A. Herpesvirus and multiple sclerosis. Herpes 2001; 8:60-63.
217. Swanborg RH, Whittum-Hudson JA, Hudson AP. Human herpesvirus 6 and Chlamydia pneumoniae as etiologic agents in multiple sclerosis-a critical review. Microbes Infect 2002; 4:1327-1333.
218. Tomsone V, Logina I, Millers A, Chapenko S, Kozireva S, Murovska M. Association of human herpesvirus 6 and human herpesvirus 7 with demyelinating diseases of the nervous system. J Neurovirol 2001; 7:564-569.
219. Marrie RA, Wolfson C. Multiple sclerosis and varicella zoster virus infection: a review. Epidemiol Infect 2001; 127:315-325.
220. Wroblewska Z, Gilden D, Devlin M, et al. Cytomegalovirus isolation from a chimpanzee with acute demyelinating disease after inoculation of multiple sclerosis brain cells. Infect Immun 1979; 25:1008-1015.
221. McHatters GR, Scham RG. Bird viruses in multiple sclerosis: combination of viruses or Marek’s alone? Neurosci Lett 1995; 188:75-76.
222. Melnick JL, Seidel E, Inoue YK, Nishibe Y. Isolation of virus from the spinal fluid of three patients with multiple sclerosis and one with amyotrophic lateral sclerosis. Lancet 1982; 1:830-833.
223. Ohara Y. Multiple sclerosis and measles virus. Jpn J Infect Dis 1999; 52:198-200.
224. Pille ER, Mzokova VM, Andreeva AP, Andzhaparidze OG. Possible role of measles, rubella and mumps viruses in multiple sclerosis. Acta Virol 1977; 21:139-145.
225. Hodge MJ, Wolfson C. Canine distemper virus and multiple sclerosis. Neurology 1997; 49:S62-S69.
226. Koprowski H, ter Meulen V. Multiple sclerosis and parainfluenza 1 virus. History of the isolation of the virus and expression of phenotypic differences between the isolated virus and Sendai virus. J Neurol 1975; 208:175-190.
227. Goswami KK, Randall RE, Lange LS, Russell WC. Antibodies against the paramyxovirus SV5 in the cerebrospinal fluids of some multiple sclerosis patients. Nature 1987; 327:244-247.
228. Stoner GL. Polyomavirus models of brain infection and the pathogenesis of multiple sclerosis. Brain Pathol 1993; 3:213-227.
229. Koprowski H, DeFreitas EC, Harper ME, et al. Multiple sclerosis and human T-cell lymphotropic retroviruses. Nature 1985; 318:154-160.
230. Graber P, Rosenmund A, Probst A, Zimmerli W. Multiple sclerosis-like illness in early HIV infection. Aids 2000; 14:2411-2413.
231. Meiering CD, Linial ML. Historical perspective of foamy virus epidemiology and infection. Clin Microbiol Rev 2001; 14:165-176.
232. Murray RS, Cai GY, Hoel K, Johnson S, Cabirac GF. Coronaviruses and multiple sclerosis. Adv Exp Med Biol 1993; 342:353-357.
233. Compston DA, Vakarelis BN, Paul E, McDonald WI, Batchelor JR, Mims CA. Viral infection in patients with multiple sclerosis and HLA-DR matched controls. Brain 1986; 109 (Pt 2):325-344.
234. Britton DE, Houff SA, Eiben RM. Possible interactions between rabies vaccination and a progressive degenerative CNS disease. Arch Neurol 1978; 35:693.
235. Nakashima I, Fujihara K, Itoyama Y. Human parvovirus B19 infection in multiple sclerosis. Eur Neurol 1999; 42:36-40.
236. Woyciechowska JL, Dambrozia J, Leinikki P, et al. Viral antibodies in twins with multiple sclerosis. Neurology 1985; 35:1176-1180.
237. Haase CG, Viazov S, Fiedler M, Koenig N, Faustmann PM, Roggendorf M. Borna disease virus RNA is absent in chronic multiple sclerosis. Ann Neurol 2001; 50:423-424.